Citations

Showing 10 of 108083 citations.

MRI of Native Knee Cartilage Delamination Injuries
White, Candace L. , Chauvin, Nancy A. , Waryasz, Gregory R. , March, Bradford T., Francavilla, Michael L.

Mayo Clinic

American Journal of Roentgenology | August 23, 2017 | Volume: 209 | Issue: 5 | Pages: W317-W321

10.2214/ajr.16.17708 | PMID 28834442 Get It

Maintenance Lenalidomide After Transplantation in Multiple Myeloma Prolongs Survival—In Most
Mıkhael, Joseph , Mikhael, Joseph R.

Mayo Clinic

Journal of Clinical Oncology | August 23, 2017 | Volume: 35 | Issue: 29 | Pages: 3269-3271

10.1200/jco.2017.74.7014 | PMID 28834440 Get It

FIRE: functional inference of genetic variants that regulate gene expression
Ioannidis, Nilah M. , Davis, Joe R., DeGorter, Marianne K. , McDonnell, Shannon K. , French, Amy J. , Battle, Alexis , Thibodeau, Stephen N. , Montgomery, Stephen B. , Bustamante, Carlos D. , Sieh, Weiva , Whittemore, Alice S. , Sieh, Weiva , Montgomery, Stephen B , Larson, Nicholas B. , Hastie, Trevor , McDonnell, Shannon K

Mayo Clinic

Bioinformatics | August 23, 2017 | Volume: 33 | Issue: 24 | Pages: 3895-3901

10.1093/bioinformatics/btx534 | PMID 28961785 Get It

Abstract Motivation Interpreting genetic variation in noncoding regions of the genome is an important challenge for personal genome analysis. One mechanism by which noncoding single nucleotide variants (SNVs) influence downstream phenotypes is through the regulation of gene expression. Methods to predict whether or not individual SNVs are likely to regulate gene expression would aid interpretation of variants of unknown significance identified in whole-genome sequencing studies. Results We developed FIRE (Functional Inference of Regulators of Expression), a tool to score both noncoding and coding SNVs based on their potential to regulate the expression levels of nearby genes. FIRE consists of 23 random forests trained to recognize SNVs in cis-expression quantitative trait loci (cis-eQTLs) using a set of 92 genomic annotations as predictive features. FIRE scores discriminate cis-eQTL SNVs from non-eQTL SNVs in the training set with a cross-validated area under the receiver operating characteristic curve (AUC) of 0.807, and discriminate cis-eQTL SNVs shared across six populations of different ancestry from non-eQTL SNVs with an AUC of 0.939. FIRE scores are also predictive of cis-eQTL SNVs across a variety of tissue types. Availability and implementation FIRE scores for genome-wide SNVs in hg19/GRCh37 are available for download at https://sites.google.com/site/fireregulatoryvariation/. Supplementary information Supplementary data are available at Bioinformatics online.
Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study
Boorjian, Stephen A. , Canter, Daniel , Ogan, Kenneth , Downs, Tracy M. , Gomella, Leonard G. , Svatek, Robert S. , Bivalacqua, Trinity J. , Grubb, Robert L. , Krupski, Tracey L. , Inman, Brant A. , Milowsky, Matthew I. , Boyd, Alan , Treasure, F. Peter, Gregory, Gillian , Sawutz, David G., Parker, Nigel, Dinney, Colin P. , Canter, Daniel J, Karsh, Lawrence I, Woods, Michael E. , Yla-Herttuala, Seppo, Parker, Nigel R, Dinney, Colin P N, Inman, Brant A , Shore, Neal D. , Karsh, Lawrence Ivan , Kamat, Ashish M. , Lotan, Yair , Lerner, Seth P. , Ylä-Herttuala, Seppo

Mayo Clinic

Journal of Clinical Oncology | August 23, 2017 | Volume: 35 | Issue: 30 | Pages: 3410-3416

10.1200/jco.2017.72.3064 | PMID 28834453 Get It

Purpose Many patients with high-risk non–muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd–IFNα/Syn3), a replication-deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC. Methods In this open-label, multicenter (n = 13), parallel-arm, phase II study ( ClinicalTrials.gov identifier: NCT01687244), 43 patients with HG BCG-refractory or relapsed NMIBC received intravesical rAd–IFNα/Syn3 (randomly assigned 1:1 to 1 × 10 11 viral particles (vp)/mL or 3 × 10 11 vp/mL). Patients who responded at months 3, 6, and 9 were retreated at months 4, 7, and 10. The primary end point was 12-month HG recurrence-free survival (RFS). All patients who received at least one dose were included in efficacy and safety analyses. Results Forty patients received rAd–IFNα/Syn3 (1 × 10 11 vp/mL, n = 21; 3 × 10 11 vp/mL, n = 19) between November 5, 2012, and April 8, 2015. Fourteen patients (35.0%; 90% CI, 22.6% to 49.2%) remained free of HG recurrence 12 months after initial treatment. Comparable 12-month HG RFS was noted for both doses. Of these 14 patients, two experienced recurrence at 21 and 28 months, respectively, after treatment initiation, and one died as a result of an upper tract tumor at 17 months without a recurrence. rAd–IFNα/Syn3 was well tolerated; no grade four or five adverse events (AEs) occurred, and no patient discontinued treatment because of an adverse event. The most frequently reported drug-related AEs were micturition urgency (n = 16; 40%), dysuria (n = 16; 40%), fatigue (n = 13; 32.5%), pollakiuria (n = 11; 28%), and hematuria and nocturia (n = 10 each; 25%). Conclusion rAd—IFNα/Syn3 was well tolerated. It demonstrated promising efficacy for patients with HG NMIBC after BCG therapy who were unable or unwilling to undergo radical cystectomy.
Faculty Opinions recommendation of Analyzing the effectiveness of vocal features in early telediagnosis of Parkinson's disease.
Caviness, John N.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 23, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.728367128.793535567 Get It

A rare case of pulmonary toxoplasmosis in a patient with undifferentiated inflammatory arthritis on chronic methotrexate and corticosteroid therapy
Abdulkareem, Abdullateef , D’Souza, Ryan S. , Patel, Nitin, Donato, Anthony A. , D'Souza, Ryan Steven, Donato, Anthony , D'Souza, Ryan S

Mayo Clinic

BMJ Case Reports | August 23, 2017 | Volume: 2017 | Issue: No issue available | Pages: bcr-2017-221252

10.1136/bcr-2017-221252 | PMID 28835429 Get It

Pulmonary toxoplasmosis is a serious pulmonary condition caused by the protozoan Toxoplasma gondii. It typically affects immunocompromised patients presenting acutely with cough, fever, myalgias, arthralgias and lymphadenopathy, and chronically with persistent cough and dyspnoea. Because of its protean features, it can mimic many more common lung conditions in the immunocompromised patient, including atypical pneumonia, Pneumocystis pneumonia and interstitial lung disease. In this article, we present the case of a 55-year-old woman who presented to our hospital with persistent dyspnoea and cough, initially suspected to have an arthritis-related interstitial lung disease. She received a final diagnosis of pulmonary toxoplasmosis after lung biopsy demonstrated Toxoplasma cysts, later confirmed by serology. Treatment with trimethoprim–sulfamethoxazole resulted in significant improvement of her respiratory symptoms after 3 months.
Patient-centered care coordination in hematopoietic cell transplantation
Khera, Nandita , Martín, Patricia, Edsall, Kristen C. , Bonagura, Anthony, Burns, Linda J. , LeMaistre, C. Frederick, Majhail, Navneet S. , Majhail, Navneet S , Juckett, Mark , King, Olivia

Mayo Clinic

Blood Advances | August 23, 2017 | Volume: 1 | Issue: 19 | Pages: 1617-1627

10.1182/bloodadvances.2017008789 | PMID 29296802 Get It

Abstract Hematopoietic cell transplantation (HCT) is an expensive, resource-intensive, and medically complicated modality for treatment of many hematologic disorders. A well-defined care coordination model through the continuum can help improve health care delivery for this high-cost, high-risk medical technology. In addition to the patients and their families, key stakeholders include not only the transplantation physicians and care teams (including subspecialists), but also hematologists/oncologists in private and academic-affiliated practices. Initial diagnosis and care, education regarding treatment options including HCT, timely referral to the transplantation center, and management of relapse and late medical or psychosocial complications after HCT are areas where the referring hematologists/oncologists play a significant role. Payers and advocacy and community organizations are additional stakeholders in this complex care continuum. In this article, we describe a care coordination framework for patients treated with HCT within the context of coordination issues in care delivery and stakeholders involved. We outline the challenges in implementing such a model and describe a simplified approach at the level of the individual practice or center. This article also highlights ongoing efforts from physicians, medical directors, payer representatives, and patient advocates to help raise awareness of and develop access to adequate tools and resources for the oncology community to deliver well-coordinated care to patients treated with HCT. Lastly, we set the stage for policy changes around appropriate reimbursement to cover all aspects of care coordination and generate successful buy-in from all stakeholders.
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma
Burri, Stuart H., Gondi, Vinai , Brown, Paul D. , Mehta, Minesh P.

Mayo Clinic

American Journal of Clinical Oncology | August 23, 2017 | Volume: 41 | Issue: 2 | Pages: 191-196

10.1097/coc.0000000000000395 | PMID 28832384 Get It

Glioblastoma (GBM) is a devastating brain tumor with poor prognosis despite advances in surgery, radiation, and chemotherapy. Survival of patients with glioblastoma remains poor, with only 1 in 4 patients alive at 2 years, and a 5-year survival rate of about 5%. Recurrence is nearly universal and, after recurrence, prognosis is poor with very short progression-free survival and overall survival (OS). Various salvage chemotherapy strategies have been applied with limited success. Tumor Treating Fields (TTFields) are a novel treatment modality approved for treatment of either newly diagnosed or recurrent GBM. TTFields therapy involves a medical device and transducer arrays to provide targeted delivery of low intensity, intermediate frequency, alternating electric fields to produce antimitotic effects selective for rapidly dividing tumor cells with limited toxicity. In the phase 3 EF-14 trial, TTFields plus temozolomide provided significantly longer progression-free survival and OS compared with temozolomide alone in patients with newly diagnosed GBM after initial chemoradiotherapy. The addition of TTFields to standard therapy improved median OS from 15.6 to 20.5 months (P=0.04). In the phase 3 EF-11 trial, for recurrent GBM, TTFields provided comparable efficacy as investigator’s choice systemic therapy, with improved patient-reported quality of life and a lower incidence of serious adverse events. Primary toxicity associated with TTFields is skin irritation generally managed with array relocation and topical treatments including antibiotics and steroids. TTFields therapy has demonstrated proven efficacy in management of GBM, including improvement in OS for patients with newly diagnosed GBM, and is under current investigation in other brain and extracranial tumors.
Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)
Lahr, Brian D. , Bailey, Kent R. , Lloyd, Robin M. , Neal‐Perry, Genevieve , Pal, Lubna , Taylor, Hugh S. , Wharton, Whitney , Harman, S. Mitchell , Miller, Virginia M. , Cintrón, Dahima , Lloyd, Robin, Santoro, Nanette F. , Manson, JoAnn E. , Naftolin, Frederick

Mayo Clinic

Menopause | August 22, 2017 | Volume: 25 | Issue: 2 | Pages: 145-153

10.1097/gme.0000000000000971 | PMID 28832429 Get It

Abstract Objective: This study determined whether two different formulations of hormone therapy (HT): oral conjugated equine estrogens (o-CEE; 0.45 mg/d, n = 209), transdermal 17β-estradiol (t-E2; 50 μg/d, n = 201) plus cyclic progesterone (Prometrium, 200 mg) or placebo (PBO, n = 243) affected sleep domains in participants of the Kronos Early Estrogen Prevention Study. Methods: Participants completed the Pittsburgh Sleep Quality Index at baseline and during the intervention at 6, 18, 36, and 48 months. Global sleep quality and individual sleep domain scores were compared between treatments using analysis of covariance, and correlated with vasomotor symptom (VMS) scores using Spearman correlation coefficients. Results: Global Pittsburgh Sleep Quality Index scores (mean 6.3; 24% with score >8) were similar across groups at baseline and were reduced (improved sleep quality) by both HT (average change −1.27 [o-CEE] and −1.32 [t-E2]) when compared with PBO (−0.60; P = 0.001 [o-CEE vs PBO] and P = 0.002 [t-E2 vs PBO]). Domain scores for sleep satisfaction and latency improved with both HT. The domain score for sleep disturbances improved more with t-E2 than o-CEE or PBO. Global sleep scores significantly correlated with VMS severity (r s = 0.170, P < 0.001 for hot flashes; r s = 0.177, P < 0.001 for night sweats). Change in scores for all domains except sleep latency and sleep efficiency correlated with change in severity of VMS. Conclusions: Poor sleep quality is common in recently menopausal women. Sleep quality improved with both HT formulations. The relationship of VMS with domains of sleep suggests that assessing severity of symptoms and domains of sleep may help direct therapy to improve sleep for postmenopausal women.
BRAF V600E Mutations Occur in a Subset of Glomus Tumors, and Are Associated With Malignant Histologic Characteristics
Dashti, Nooshin K. , Bahrami, Armita , Lee, Seung Joon , Jenkins, Sarah M. , Folpe, Andrew L. , Boland, Jennifer M. , Karamzadeh Dashti, Nooshin, Rodríguez, Fausto J.

Mayo Clinic

American Journal of Surgical Pathology | August 22, 2017 | Volume: 41 | Issue: 11 | Pages: 1532-1541

10.1097/pas.0000000000000913 | PMID 28834810 Get It

Glomus tumors are rare mesenchymal neoplasms with a phenotype akin to the modified smooth muscle cells of the glomus body. Most are benign, but rare examples show malignant histologic characteristics and aggressive behavior. We recently encountered a malignant glomus tumor with BRAF V600E mutation. We sought to study a large cohort for this mutation, with particular attention to associated malignant histologic characteristics. Tumors were classified based on WHO criteria as benign, uncertain malignant potential (glomus tumors of uncertain malignant potential—GT-UMP), or malignant. Tumors were screened for BRAF V600E by immunohistochemistry, and positive staining was evaluated further by Sanger sequencing. A total of 102 glomus tumors were included and classified as benign (57, 56%), GT-UMP (15, 15%) and malignant (30, 29%). Tumors occurred in patients aged 8 to 89.9 years (median: 50.2), without sex predilection (55% men). Most occurred in the superficial soft tissue (84%) and upper extremities (55%). Six of 95 tested cases had BRAF V600E mutation (6%), including 0 of 57 benign tumors, 3 of 14 GT-UMP (21%), and 3 of 24 malignant tumors (12%). Follow-up was obtained for 59 cases (median: 75.7 mo, range: 7.8 to 268.5). Three of 11 malignant tumors (27%) had progressive disease: 1 with metastasis to brain and heart, 1 with enlarging residual disease, and 1 with recurrence. Two of 4 GT-UMP (50%) had progressive disease: 1 with metastasis to lung, and 1 with local recurrence (50%). Three of 44 benign tumors (7%) had local recurrence. Two of 5 patients with BRAF V600E had progression, including 1 GT-UMP with local recurrence and 1 malignant tumor with enlarging residual disease. In summary, BRAF V600E mutation was detected in 6% of glomus tumors, all of which were malignant or GT-UMP. This mutation may be associated with a malignant phenotype, although study of additional cases is needed. In patients with progressive disease, BRAF could be a promising therapeutic target.